323 related articles for article (PubMed ID: 35469916)
1. Cancer immunotherapy resistance: The impact of microbiome-derived short-chain fatty acids and other emerging metabolites.
Hersi F; Elgendy SM; Al Shamma SA; Altell RT; Sadiek O; Omar HA
Life Sci; 2022 Jul; 300():120573. PubMed ID: 35469916
[TBL] [Abstract][Full Text] [Related]
2. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
[TBL] [Abstract][Full Text] [Related]
3. Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend?
Zhao H; Wang D; Zhang Z; Xian J; Bai X
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956752
[TBL] [Abstract][Full Text] [Related]
4. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors.
Wang J; Zhu N; Su X; Yang R
Cancer Lett; 2024 Feb; 582():216582. PubMed ID: 38065401
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota-derived short-chain fatty acids and colorectal cancer: Ready for clinical translation?
Hou H; Chen D; Zhang K; Zhang W; Liu T; Wang S; Dai X; Wang B; Zhong W; Cao H
Cancer Lett; 2022 Feb; 526():225-235. PubMed ID: 34843863
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota-derived short-chain fatty acids and kidney diseases.
Li L; Ma L; Fu P
Drug Des Devel Ther; 2017; 11():3531-3542. PubMed ID: 29270002
[TBL] [Abstract][Full Text] [Related]
9. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
10. Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors.
Nomura M; Nagatomo R; Doi K; Shimizu J; Baba K; Saito T; Matsumoto S; Inoue K; Muto M
JAMA Netw Open; 2020 Apr; 3(4):e202895. PubMed ID: 32297948
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota interactions with antitumor immunity in colorectal cancer: From understanding to application.
Zhuang YP; Zhou HL; Chen HB; Zheng MY; Liang YW; Gu YT; Li WT; Qiu WL; Zhou HG
Biomed Pharmacother; 2023 Sep; 165():115040. PubMed ID: 37364479
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer.
Chang AE; Golob JL; Schmidt TM; Peltier DC; Lao CD; Tewari M
Trends Cancer; 2021 Jul; 7(7):583-593. PubMed ID: 33741313
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota and immunotherapy of renal cell carcinoma.
Bibbò S; Porcari S; Del Vecchio LE; Severino A; Mullish BH; Ianiro G; Gasbarrini A; Cammarota G
Hum Vaccin Immunother; 2023 Dec; 19(3):2268982. PubMed ID: 37955340
[TBL] [Abstract][Full Text] [Related]
14. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
[TBL] [Abstract][Full Text] [Related]
15. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors.
Simpson RC; Shanahan ER; Scolyer RA; Long GV
Nat Rev Clin Oncol; 2023 Oct; 20(10):697-715. PubMed ID: 37488231
[TBL] [Abstract][Full Text] [Related]
16. Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain-gut axis alterations.
van de Wouw M; Boehme M; Lyte JM; Wiley N; Strain C; O'Sullivan O; Clarke G; Stanton C; Dinan TG; Cryan JF
J Physiol; 2018 Oct; 596(20):4923-4944. PubMed ID: 30066368
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of nutritional short-chain fatty acids (SCFAs) against cancer via modulation of hematopoiesis.
Thiruvengadam M; Subramanian U; Venkidasamy B; Thirupathi P; Samynathan R; Shariati MA; Rebezov M; Chung IM; Rengasamy KRR
Crit Rev Food Sci Nutr; 2023; 63(6):827-844. PubMed ID: 34319824
[TBL] [Abstract][Full Text] [Related]
18. Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites.
Malczewski AB; Ketheesan N; Coward JIG; Navarro S
Front Immunol; 2021; 12():624434. PubMed ID: 34305883
[TBL] [Abstract][Full Text] [Related]
19. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges.
Bouferraa Y; Chedid A; Amhaz G; El Lakkiss A; Mukherji D; Temraz S; Shamseddine A
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360802
[TBL] [Abstract][Full Text] [Related]
20. Role of microbiota-derived short-chain fatty acids in nervous system disorders.
Mirzaei R; Bouzari B; Hosseini-Fard SR; Mazaheri M; Ahmadyousefi Y; Abdi M; Jalalifar S; Karimitabar Z; Teimoori A; Keyvani H; Zamani F; Yousefimashouf R; Karampoor S
Biomed Pharmacother; 2021 Jul; 139():111661. PubMed ID: 34243604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
